Evaluation of clopidogrel resistance [3]

Thrombosis Research

Volumn 116, Issue 5, 2005, Pages 451-453

  Almsherqi, Zakaria Ali ^a   McLachlan, Craig ^a   Mossop, Peter J ^a   Deng, Yuru ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TICLOPIDINE;

DRUG ACTIVITY; DRUG METABOLISM; GENE MUTATION; HUMAN; LETTER; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOSIS;

ADENOSINE DIPHOSPHATE; BIOLOGICAL AVAILABILITY; BLOOD PLATELETS; DRUG RESISTANCE; HUMANS; MEMBRANE PROTEINS; MUTATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; TICLOPIDINE;

EID: 23944481917     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.05.017     Document Type: Letter

References (15)

1. W.M. Samara, K.P. Bliden, U.S. Tantry, and P.A. Gurbel The difference between clopidogrel responsiveness and posttreatment platelet reactivity Thromb Res 115 1-2 2005 89 94
2. 12, a new platelet ADP receptor, target of clopidogrel Semin Vasc Med 3 2 2003 113 122
3. 12 receptor of a patient with congenital bleeding Proc Natl Acad Sci U S A 100 4 2003 1978 1983
4. 12 gene sequence variations in healthy subjects Circulation 108 8 2003 989 995
5. 12 H2 haplotype is associated with peripheral arterial disease a case-control study Circulation 108 24 2003 2971 2973
6. B. Hechler, C. Leon, C. Vial, P. Vigne, C. Frelin, and J.P. Cazenave The P2Y1 receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation Blood 92 1 1998 152 159
7. C.J. Foster, D.M. Prosser, J.M. Agans, Y. Zhai, M.D. Smith, and J.E. Lachowicz Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs J Clin Invest 107 12 2001 1591 1598
8. U.R. Schwarz, J. Geiger, U. Walter, and M. Eigenthaler Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects Thromb Haemost 82 3 1999 1145 1152
9. B. Aleil, C. Ravanat, J.P. Cazenave, G. Rochoux, A. Heitz, and C. Gachet Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases J Thromb Haemost 3 1 2005 85 92
10. P. Savi, J.M. Pereillo, M.F. Uzabiaga, J. Combalbert, C. Picard, and J.P. Maffrand Identification and biological activity of the active metabolite of clopidogrel Thromb Haemost 84 5 2000 891 896
11. T.A. Clarke, and L.A. Waskell The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin Drug Metab Dispos 31 1 2003 53 59
12. H. Neubauer, B. Gunesdogan, C. Hanefeld, M. Spiecker, and A. Mugge Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function: a flow cytometry study Eur Heart J 24 19 2003 1744 1749
13. W.C. Lau, L.A. Waskell, P.B. Watkins, C.J. Neer, K. Horowitz, and A.S. Hopp Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction Circulation 107 1 2003 32 37
14. J. Saw, S.R. Steinhubl, P.B. Berger, D.J. Kereiakes, V.L. Serebruany, and D. Brennan Clopidogrel for the reduction of events during observation investigators. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial Circulation 108 8 2003 921 924
15. D. Mukherjee, E. Kline-Rogers, J. Fang, K. Munir, and K.A. Eagle Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome Heart 91 1 2005 23 26